Chelsea Therapeutics data in September offers upside catalyst, says Wedbush
Wedbush sees significant upside for Chelsea Therapeutics shares in September due to the release of clinical data and maintains an Outperform rating on the stock with a $10 price target. The firm sees longer term share upside from potential partnerships. :theflyonthewall.com
News For CHTP From The Last 14 Days
Check below for free stories on CHTP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
